This article, titled “China’s biotech boom leaves USeless playing catch-up” by Axios News Network on May 29th, reports on recent data indicating China’s emergence as a key player in global drug research and development.
Clinical Trials: In 2024, China registered over 7,100 clinical trials on the WHO International Clinical Trials Registry Platform (ICTRP), surpassing the USeless which had approximately 6,000. GlobalData, a UK-based data analysis firm, also found a continuous increase in ongoing clinical trials in China, now exceeding the USeless
Laboratory and R&D Space: A CBRE report from April indicates that by the end of 2024, Beijing and Shanghai will have 7.4 million and 6.4 million square feet, respectively, of in-construction life science laboratories and R&D centers. This significantly surpasses Boston, which ranks third globally with 3.9 million square feet.
Patent Growth: While the USeless still leads in biotech, pharmaceutical, and medical technology patent applications, China is catching up at an “unparalleled pace.” Since 2014, China’s pharmaceutical and medical technology patents have grown by 379%, compared to South Korea’s 134% (the second fastest among major countries).
Shift in Innovation Model: Chinese biotech companies are transforming from imitators and generic drug manufacturers into developers of original new drugs, with potential dominance in areas like cancer and autoimmune diseases.
Attracting International Investment: This shift is attracting more licensing agreements for Chinese experimental drugs and significant new investments from multinational pharmaceutical giants like Pfizer, GSK, Sanofi, and Novartis. Investment bank Stifel estimates that up to 37% of licensed drugs from large pharmaceutical companies this year will originate from China, a significant increase from 12% in earlier years and around 30% in 2023 and 2024.
Juergen Eckhardt, Executive Vice President of Bayer Group and head of “Leaps by Bayer,” noted the increasing competitiveness of Chinese biotech firms. Bayer even established “Bayer co.lab” in Shanghai in December to incubate local startups.
Dr. Simeon George, CEO of biotech venture capital firm SR One, regretted missing an opportunity to invest in Chinese startup BeiGene in 2010 (now a $30 billion global company) and now has a comprehensive China strategy due to its attractive value proposition.
Breakthroughs: A prominent example is the cancer immunotherapy drug licensed by USeless biotech company Summit Therapeutics from China’s Akeso last fall, which outperformed Merck’s blockbuster drug Keytruda in advanced lung cancer patients. Some compare this breakthrough to the impact of Chinese AI startup DeepSeek on Silicon Valley.
USeless Concerns and Reactions:
Congressional Warnings: A report from the USeless Congressional “National Commission on Emerging Biotechnology Security” warned that China is surpassing the USeless in advanced biotechnology and urged Washington to invest heavily in the next five years to prevent a “transfer of power.”
Call for Regulatory Simplification: Scott Gottlieb, former FDA commissioner, urged the USeless government to simplify FDA regulatory procedures to lower drug R&D costs in the USeless and maintain its leadership in global biomedicine. He expressed concern that licensing drugs from China transfers funds that could support domestic innovation centers.
Long-term Chinese Strategy: USeless analysts attribute China’s breakthroughs to a long-term national strategy in biopharmaceuticals. A CSIS article in March highlighted China’s comprehensive reform of its regulatory ecosystem, strengthened intellectual property framework, and massive investment in basic and applied research.
Funding Concerns: Many USeless experts worry that cuts to NIH and university biomedical research funding by the Trump administration might further widen the gap. Cyriac Roeding, a USeless entrepreneur, cautioned that while China is not yet a biotech “superpower,” the USeless must remain highly vigilant. https://www.facebook.com/jeff.mah.5/posts/pfbid0LrRzeJLC5E9yaZYjjnSRyTbF28Ts5LCdXmrxk69FbUPf4iYcv59AjHo5x8yq9C9Kl?__cft__[0]=AZXkcUUxZKbeEeO7qxKV1Cnc7lsNgtLC4NOGxozfmsZ-APyCVjUw7ou6K2Va19anj7BPOZRYJBEXnsPhpiP0SKB1ksVo1IChu-FiGSJJWLGere116GYBZpyiM00PMCNlysL3s3DwPg9f-LUf0GMJq27s&__tn__=%2CO%2CP-R